USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: VAXIN INC.
City: Gaithersburg
State: MD
Zip+4: 20878-1791
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $662,195.00 7
SBIR Phase II $955,357.00 1
STTR Phase I $500,000.00 6
STTR Phase II $282,625.00 1

Award List:

NONINVASIVE DELIVERY OF SKIN TARGETED FLU VACCINES

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tang, De-chu
Award Amount: $100,000.00

Prediction of Hyperbaric Oxygen Toxicity

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency / Branch: DOD / NAVY
Principal Investigator: Felix Siegel, Principle Scientist
Award Amount: $69,700.00
Abstract:
Dengue virus (DV) is a serious threat to people including military personal in endemic areas. So far no prophylactic vaccine is available. The aim of this study is to develop a DV vaccine patch. Transcutaneous vaccination by topical application of apatch requires a lower level of medical… More

Noninvasive delivery of skin-targeted anthrax vaccines

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dechu C. Tang
Award Amount: $100,000.00
Abstract:
DESCRIPTION (Provided by Applicant): Our aim is to develop a simple method for the delivery of anthrax vaccines by topical application of adenovirus-based expression vectors using a skin patch in a noninvasive mode. The hypothesis is that the expression of Bacillus anthracis… More

NONINVASIVE DELIVERY OF SKIN-TARGETED RABIES VACCINES

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dechu C. Tang
Award Amount: $100,000.00
Abstract:
DESCRIPTION: (Adapted from Applicant's Abstract) Our aim is to develop a simple and effective method for the delivery of rabies vaccines by topical application of adenovirus-based expression vectors using a skin patch in a noninvasive mode. The hypothesis is… More

SKIN-PATCH VACCINATION AGAINST ALZHEIMER'S DISEASE

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF ALABAMA, BIRMINGHAM
Principal Investigator: Kenichiro Fukuchi
Award Amount: $100,000.00
RI Contact: N/A
Abstract:
Alzheimer's disease (AD) and inclusion body myositis (IBM) share a number of common pathologies such as deposits of amyloid beta-protein (AB) and paired helical filaments, although such pathologies are mostly restricted to brain for AD and to muscle for IBM. Transgenic mice (Tg 13592) that express… More

IMMUNO-ENHANCEMENT OF SKIN PATCH ANTHRAX VACCINATION

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF ALABAMA AT BIRMINGHAM
Principal Investigator: Hui Xu
Award Amount: $100,000.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): In the wake of bio-terrorism, anthrax has become a real concern for public. Anthrax is listed as a category A biological disease by the CDC. Inhalation of anthrax spores can result in death due to rapid fatal hemorrhage. Since anthrax aerosol is odorless,… More

Boost-Phase Sub-Unit Vaccine Development for Binary Vaccines Against Infectious Diseases and Biological Warfare Agents

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency / Branch: DOD / NAVY
Principal Investigator: Felix Siegel, Principle Scientist
Award Amount: $69,997.00
Abstract:
Malaria is a serious threat to people including military personal in endemic areas. So far no prophylactic vaccine is available. The aim of this study is to develop a powerful prime/boost vaccination protocol against malaria using DNA vaccines to primethe immune system and recombinant adenovirus… More

In-ovo vaccination/avian influenza/bird/human

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dechu C. Tang
Award Amount: $111,797.00
Abstract:
DESCRIPTION (provided by applicant): The aim of this proposal is to develop an effective and rapid method for disrupting the poultry-to- human transmission of avian influenza by in ovo injection of flu vaccines that can be mass- administered with a mechanized injector. The hypothesis is that… More

Adenovirus vectored vaccines for Alzheimer's disease

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF ILLINOIS
Principal Investigator: Kenichiro Fukuchi
Award Amount: $100,000.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common neurodegenerative disease in the elderly. To date, no satisfactory treatment is available for AD. One of the pathological hallmarks of AD is deposits of amyloid protein (Aa) in neuritic plaques and cerebral vessels.… More

In-ovo vaccination/avian influenza/bird/human

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $955,357.00
Abstract:
DESCRIPTION (provided by applicant): The aim of this proposal is to develop an effective and rapid method for disrupting the poultry-to-human transmission of avian influenza by in ovo injection of adenovirus-vectored avian influenza vaccines that can be ma ss-produced in cultured cells and… More

Acne Vaccines Targeting a Surface Sialidase and a Secreted CAMP Factor Toxin

Award Year / Program / Phase: 2008 / STTR / Phase I
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $100,000.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Propionibacterium acnes (P. acnes) is most notably recognized for its role in acne vulgaris, the most common skin disease, affecting 85-100% of the population at some point in their lives. Current treatments for vulgari s acne using isotretinoin (13-cis-retinoic… More

Development of a simple and effective therapy against post-exposure anthrax

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jianfeng Zhang – 205-934-7432
Award Amount: $110,701.00
Abstract:
DESCRIPTION (provided by applicant): The use of both vaccination and antibiotic therapy is the most effective approach against inhalational anthrax. Unfortunately, there are two significant problems associated with current post-exposure prophylaxis (PEP):1) the limitations of the anthrax vaccine… More